This, according to India news outlets, this past afternoon, India time:
. . . .A bench of Justices S Ravindra Bhat and S K Mishra issued a notice to Glenmark and sought its reply by May 22 on the US firm’s plea challenging the single judge order. . . .
On April 5, a single judge bench of Justice Rajiv Sahai Endlaw, in an interim order, had refused to restrain the Indian company from manufacturing and selling its anti-diabetes medicines.
Justice Endlaw had said, “I do not find the plaintiff (MSD) to have made out a case for grant of interim relief. The application is accordingly dismissed but with a direction to the defendant (Glenmark Pharmaceuticals) to diligently maintain accounts of the manufacturing/production and sales of the infringing products and to file the same before this court with advance copy to the counsel for the plaintiff. . . .”
So — stay tuned for a late-May report out of India, here.